Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen

Mukhtyar, Chetan ORCID: https://orcid.org/0000-0002-9771-6667, Cate, Heidi, Graham, Conor, Merry, Peter, Mills, Karen, Misra, Aseema and Jones, Colin (2019) Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen. Rheumatology Advances in Practice, 3 (1). ISSN 2514-1775

Preview

PDF (Published_Version) - Published Version Available under License Creative Commons Attribution Non-commercial. Download (523kB) | Preview

Abstract

We have reviewed the literature to form a bespoke regimen for daily oral prednisolone (DP) in GCA. Initial DP in clinical trials is 40-60 mg daily, but relapse rates are 67-92%. Cumulative prednisolone (CP) of 3.2 and 3.9 g (at 6 months) resulted in a relapse rate of 83 and 67%, respectively; and 3 and 3.9 g (at 12 months) resulted in 92 and 82% relapse, respectively. CP was 6.2-7.1 g in the first year. Mean DP was 18.8 mg at 3 months and 6.6-7.4 mg at 12 months. The duration of treatment with prednisolone for GCA was 22-26 months. The CP to achieve discontinuation was 6.5-12.1 g. Using these data, the Norwich regimen starts DP at 1 mg/kg/day of lean body mass, discontinuing over 100 weeks. For the average UK woman, initial DP is 45 mg daily, reaching 21 mg daily by 12 weeks and 6 mg daily by 52 weeks. The CP for the average UK woman would be 6.5 g at 52 weeks and 7.4 g to discontinuation.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	LivePure Connector
Date Deposited:	27 Nov 2019 01:59
Last Modified:	08 Nov 2023 02:13
URI:	https://ueaeprints.uea.ac.uk/id/eprint/73081
DOI:	10.1093/rap/rkz001

Downloads

Actions (login required)

View Item